NCT06393504View on ClinicalTrials.gov

Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

Active, not recruitingOBSERVATIONAL
Enrollment

2,095

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Insomnia Disorder
Interventions
DRUG

Daridorexant

Daridorexant received during or shortly prior to pregnancy.

DRUG

Non-orexin receptor antagonist insomnia medication

Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.

OTHER

No insomnia medication

No insomnia medication received during or shortly prior to pregnancy.

Trial Locations (1)

19801

Carelon Research, Wilmington

Sponsors

Collaborators (1)

Carelon Research
All Listed Sponsors
collaborator

Carelon Research

OTHER

lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY